The mechanism, efficacy and safety of anti-placental growth factor (PlGF) antibodies in CNV formation in a mouse model for ARMD

Sara Van de Veire; Stanley A. Vinores; Lieve Moons; Peter Carmeliet; Ingeborg Stalmans

Back

The mechanism, efficacy and safety of anti-placental growth factor (PlGF) antibodies in CNV formation in a mouse model for ARMD

Article 2007 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2008

Anti-PlGF (Placental Growth Factor) Reduces Choroidal Neovascularization in a Mouse Model of Age-Related Macular Degeneration (ARMD)

Sara Van de Veire, Stanley A. Vinores, Aleksandar Perić, Massimiliano Mazzone, G. Moons, J M Stassen, Agnès Noël, Ingeborg Stalmans, Peter Carmeliet

Article2007

Placental growth factor (PlGF) inhibition reduces choroidal neovascularization in a mouse model for age‐related macular degeneration

Sara Van de Veire, G. Moons, SA Vinores, Peter Carmeliet, Ingeborg Stalmans

Article2008

Anti‐PlGF (placental growth factor) as a safer alternative for anti‐VEGF in the treatment of age‐related macular degeneration (AMD)?

Sara Van de Veire, Stanley A. Vinores, Aleksandar Perić, Massimiliano Mazzone, Lieve Moons, Peter Carmeliet, Ingeborg Stalmans

Article2009

Role of Placental Growth Factor in Mesenteric Neoangiogenesis in a Mouse Model of Portal Hypertension

Christophe Van Steenkiste, Anja Geerts, Eline Vanheule, Hans Van Vlierberghe, Filip De Vos, Kim Olievier, Christophe Casteleyn, Debby Laukens, Martine De Vos, Jean–Marie Stassen, Peter Carmeliet, Isabelle Colle

Article2002

Potential role of the VEGF homologue placental growth factor (PlGF) in neurogenesis

Christian Nern, Anne Schänzer, H.M. Kuhn, Lieve Moons, Peter Carmeliet, KH Plate